Clinical trial
A Phase II, Open Label, Two-Arm Study of Therapeutic Iobenguane (131I) as Single Agent or in Combination With Vorinostat for Recurrent or Progressive High- Risk Neuroblastoma Subjects (OPTIMUM TRIAL)
NCT03561259 is registered in ClinicalTrials.gov with Jubilant DraxImage Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Open Label, Two-Arm Study of Therapeutic Iobenguane (131I) as Single Agent or in Combination With Vorinostat for Recurrent or Progressive High- Risk Neuroblastoma Subjects (OPTIMUM TRIAL)
- Lead sponsor
- Jubilant DraxImage Inc.
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- October 21, 2019
- Completion date
- April 30, 2025
- Enrollment
- 60 (estimated)
- Sites
- 21
Conditions
As the registry lists them; a condition with its own page is linked.